1. At a Glance
Kronox Lab Sciences Ltd (KLSL) is a specialty chemicals player making high-purity fine chemicals for pharma, nutraceutical, food, and industrial applications. With 33% operating margins and ROCE near 44%, this ₹611 Cr market cap company runs lean, clean, and debt-free. It’s the small-cap lab nerd quietly acing the class while bigger chemical giants fight over who can blow up the beaker first.
2. Introduction
Founded in 2008, Kronox’s pitch is simple — make chemicals so pure that even your high school chemistry teacher would cry tears of joy. They supply 185+ products, ranging from pharmaceutical excipients to reagents, to a global customer base that demands consistency over volume.
Unlike most chemical stocks that yo-yo with commodity cycles, Kronox plays in the specialty niche — less exposure to price wars, more focus on quality and customisation. The growth here is a little more “measured titration” than “exothermic reaction.”
3. Business Model (WTF Do They Even Do?)
Main Segments:
- High Purity Reagents – lab-grade inputs for research, testing, and industrial analysis.
- Pharma/Nutra/Food Chemicals – excipients and specialty additives.
- Metallic & Phosphate Chemicals – niche industrial uses.
Moat: Product purity standards, in-house R&D,
and a wide SKU base (185+ products) reduce dependency on any single client or segment.
Revenue Mix: Domestic + export sales, diversified across regulated and non-regulated markets.
4. Financials Overview
Latest Quarter (Q1 FY26):
- Revenue: ₹24.29 Cr (-3.6% YoY)
- Operating Profit: ₹7.97 Cr
- OPM: 32.8%
- Net Profit: ₹6.28 Cr
- EPS: ₹1.69
Fresh P/E Calculation:
Annualized EPS = ₹1.69 × 4 = ₹6.76
At CMP ₹164 → P/E = 24.26 (slightly above industry median, justified by high ROCE).
TTM:
- Revenue: ₹99 Cr
- Net Profit: ₹26 Cr
- ROE: 32.6%
- Dividend Yield: 0.30% (token payout — more like a tip jar than an income stream).
5. Valuation (Fair Value RANGE only)
| Method | Basis | Multiple / Assumption | Value (₹ Cr) | Per Share (₹) |
|---|---|---|---|---|
| P/E | EPS ₹6.76 × 20–25 | 20x – 25x | 540 – 675 | 145 – 181 |
| EV/EBITDA | EBITDA ₹33 Cr × 12–14 | 12x – 14x | 396 – 462 | 148 – 173 |
| DCF | 15% growth, 12% discount, 10 years | Conservative | ~₹650 Cr | ~₹175 |
Fair Value Range: ₹148
